1
|
Jandali B, Salazar GA, Hudson M, Fritzler MJ, Lyons MA, Estrada-Y-Martin RM, Charles J, Terracina KA, Mayes MD, Assassi S. The Effect of Anti-Scl-70 Antibody Determination Method on Its Predictive Significance for Interstitial Lung Disease Progression in Systemic Sclerosis. ACR Open Rheumatol 2022; 4:345-351. [PMID: 35048554 PMCID: PMC8992461 DOI: 10.1002/acr2.11398] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2021] [Revised: 11/07/2021] [Accepted: 11/23/2021] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVE The objective of this study was to assess the predictive significance of anti-Scl-70 (anti-topoisomerase I) antibodies, as determined by three different methods, for decline in forced vital capacity (FVC) within the first year of follow-up in patients with systemic sclerosis (SSc)-related interstitial lung disease (ILD). METHODS Patients in the Genetics Versus Environment in Scleroderma Outcome Study cohort who had ILD (verified by imaging) and available FVC% at enrollment, plus 12 to 18 months thereafter, were examined. All patients had a disease duration of 5 years or less at enrollment. The annualized percentage change in FVC% at 1 year follow-up was the outcome variable. Anti-Scl-70 antibodies were determined by passive immunodiffusion (ID) against calf thymus extract, chemiluminescent immunoassay (CIA), and line blot immunoassay (LIA). RESULTS Ninety-one patients with a mean disease duration of 2.36 years were included. Anti-Scl-70 antibodies by ID predicted a faster rate of FVC% decline (b = -0.06, P = 0.04). None of the other clinical or serological variables significantly predicted ILD progression. Interestingly, anti-Scl-70 antibodies as determined by CIA and LIA were not significant predictors of FVC decline (P = 0.26 and 0.64, respectively). The observed level of agreement between ID and LIA was moderate (κ = 0.568), whereas it was good between ID and CIA (κ = 0.66). CONCLUSION Anti-Scl-70 antibodies determined by ID predicted faster FVC decline in patients with SSc-related ILD. Notably, both CIA and LIA for the same antibody did not predict rate of FVC decline at their current cutoffs of positivity. The discrepancy observed between anti-Scl-70 antibody assays can have relevant implications for clinical care and trial enrichment strategies in SSc-ILD.
Collapse
Affiliation(s)
- Bochra Jandali
- McGovern Medical School, The University of Texas Health Science Center at Houston
| | - Gloria A Salazar
- McGovern Medical School, The University of Texas Health Science Center at Houston
| | - Marie Hudson
- McGill University and Jewish General Hospital, Montreal, Quebec, Canada
| | - Marvin J Fritzler
- Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Marka A Lyons
- McGovern Medical School, The University of Texas Health Science Center at Houston
| | | | - Julio Charles
- McGovern Medical School, The University of Texas Health Science Center at Houston
| | | | - Maureen D Mayes
- McGovern Medical School, The University of Texas Health Science Center at Houston
| | - Shervin Assassi
- McGovern Medical School, The University of Texas Health Science Center at Houston
| |
Collapse
|
2
|
Naovarat BS, Lyons MA, Dau JD, Nguyen BY, Salazar GA, Williams FM, Reveille JD. Factors Associated With Knee Osteoarthritis in an Outpatient HIV-1 Clinic Setting: Management and Follow-up. J Clin Rheumatol 2022; 28:e308-e311. [PMID: 34117189 DOI: 10.1097/rhu.0000000000001743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Benjamin S Naovarat
- From the Division of Rheumatology, The University of Texas-McGovern Medical School, Houston, TX
| | - Marka A Lyons
- From the Division of Rheumatology, The University of Texas-McGovern Medical School, Houston, TX
| | - Jonathan D Dau
- Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
| | - Binh Y Nguyen
- From the Division of Rheumatology, The University of Texas-McGovern Medical School, Houston, TX
| | - Gloria A Salazar
- From the Division of Rheumatology, The University of Texas-McGovern Medical School, Houston, TX
| | - Francis M Williams
- From the Division of Rheumatology, The University of Texas-McGovern Medical School, Houston, TX
| | - John D Reveille
- From the Division of Rheumatology, The University of Texas-McGovern Medical School, Houston, TX
| |
Collapse
|
3
|
Skaug B, Lyons MA, Swindell WR, Salazar GA, Wu M, Tran TM, Charles J, Vershel CP, Mayes MD, Assassi S. Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time. Ann Rheum Dis 2021; 81:516-523. [PMID: 34937693 DOI: 10.1136/annrheumdis-2021-221352] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2021] [Accepted: 11/29/2021] [Indexed: 11/04/2022]
Abstract
OBJECTIVES Determine relationships between skin gene expression and systemic sclerosis (SSc) clinical disease features, and changes in skin gene expression over time. METHODS A total of 339 forearm skin biopsies were obtained from 113 SSc patients and 44 matched healthy controls. 105 SSc patients had a second biopsy, and 76 had a third biopsy. Global gene expression profiling was performed, and differentially expressed genes and cell type-specific signatures in SSc were evaluated for relationships to modified Rodnan Skin Score (mRSS) and other clinical variables. Changes in skin gene expression over time were analysed by mixed effects models and principal component analysis. Immunohistochemical staining was performed to validate conclusions. RESULTS Gene expression dysregulation was greater in SSc patients with affected skin than in those with unaffected skin. Immune cell and fibroblast signatures positively correlated with mRSS. High baseline immune cell and fibroblast signatures predicted higher mRSS over time, but were not independently predictive of longitudinal mRSS after adjustment for baseline mRSS. In early diffuse cutaneous SSc, immune cell and fibroblast signatures declined over time, and overall skin gene expression trended towards normalisation. On immunohistochemical staining, most early diffuse cutaneous SSc patients with high baseline T cell and macrophage numbers had declines in these numbers at follow-up. CONCLUSIONS Skin thickness in SSc is related to dysregulated immune cell and fibroblast gene expression. Skin gene expression changes over time in early diffuse SSc, with a tendency towards normalisation. These observations are relevant for understanding SSc pathogenesis and could inform treatment strategies and clinical trial design.
Collapse
Affiliation(s)
- Brian Skaug
- Division of Rheumatology, University of Texas Health Science Center Houston, McGovern Medical School, Houston, Texas, USA
| | - Marka A Lyons
- Division of Rheumatology, University of Texas Health Science Center Houston, McGovern Medical School, Houston, Texas, USA
| | - William R Swindell
- Department of Internal Medicine, The Jewish Hospital, Cincinnati, Ohio, USA
| | - Gloria A Salazar
- Division of Rheumatology, University of Texas Health Science Center Houston, McGovern Medical School, Houston, Texas, USA
| | - Minghua Wu
- Division of Rheumatology, University of Texas Health Science Center Houston, McGovern Medical School, Houston, Texas, USA
| | - Tuan M Tran
- Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Julio Charles
- Division of Rheumatology, University of Texas Health Science Center Houston, McGovern Medical School, Houston, Texas, USA
| | - Connor P Vershel
- Division of Rheumatology, University of Texas Health Science Center Houston, McGovern Medical School, Houston, Texas, USA
| | - Maureen D Mayes
- Division of Rheumatology, University of Texas Health Science Center Houston, McGovern Medical School, Houston, Texas, USA
| | - Shervin Assassi
- Division of Rheumatology, University of Texas Health Science Center Houston, McGovern Medical School, Houston, Texas, USA
| |
Collapse
|
4
|
Rodarte J, Akhavan B, Salazar GA, Cherian SV, Estrada-Y-Martin RM. 52-Year-Old With Epistaxis, Hemoptysis, Hoarseness, and Weight Loss. Chest 2021; 159:e225-e230. [PMID: 34022023 DOI: 10.1016/j.chest.2020.10.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2020] [Revised: 09/30/2020] [Accepted: 10/05/2020] [Indexed: 11/15/2022] Open
Abstract
CLINICAL PRESENTATION A 52-year-old man presented with hemoptysis of 2 weeks' duration. He had been experiencing hoarseness, right-sided pleuritic chest pain, subjective fevers, chills, night sweats, and 10 pounds weight loss for the previous 2 months. He additionally reported severe frontal headaches, nasal congestion, and intermittent epistaxis, which had been present for a year before his current presentation. He had worked in construction and denied tobacco or illicit drug use.
Collapse
Affiliation(s)
- Julio Rodarte
- Department of Internal Medicine, University of Texas Health-McGovern Medical School, Houston, TX
| | - Bobak Akhavan
- Department of Internal Medicine, University of Texas Health-McGovern Medical School, Houston, TX
| | - Gloria A Salazar
- Divisions of Rheumatology and Clinical Immunogenetics, University of Texas Health-McGovern Medical School, Houston, TX
| | - Sujith V Cherian
- Divisions of Pulmonary, Critical Care and Sleep Medicine, University of Texas Health-McGovern Medical School, Houston, TX.
| | - Rosa M Estrada-Y-Martin
- Divisions of Pulmonary, Critical Care and Sleep Medicine, University of Texas Health-McGovern Medical School, Houston, TX
| |
Collapse
|
5
|
Pachera E, Assassi S, Salazar GA, Stellato M, Renoux F, Wunderlin A, Blyszczuk P, Lafyatis R, Kurreeman F, de Vries-Bouwstra J, Messemaker T, Feghali-Bostwick CA, Rogler G, van Haaften WT, Dijkstra G, Oakley F, Calcagni M, Schniering J, Maurer B, Distler JH, Kania G, Frank-Bertoncelj M, Distler O. Long noncoding RNA H19X is a key mediator of TGF-β-driven fibrosis. J Clin Invest 2021; 130:4888-4905. [PMID: 32603313 DOI: 10.1172/jci135439] [Citation(s) in RCA: 46] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Accepted: 06/17/2020] [Indexed: 12/22/2022] Open
Abstract
TGF-β is a master regulator of fibrosis, driving the differentiation of fibroblasts into apoptosis-resistant myofibroblasts and sustaining the production of extracellular matrix (ECM) components. Here, we identified the nuclear long noncoding RNA (lncRNA) H19X as a master regulator of TGF-β-driven tissue fibrosis. H19X was consistently upregulated in a wide variety of human fibrotic tissues and diseases and was strongly induced by TGF-β, particularly in fibroblasts and fibroblast-related cells. Functional experiments following H19X silencing revealed that H19X was an obligatory factor for TGF-β-induced ECM synthesis as well as differentiation and survival of ECM-producing myofibroblasts. We showed that H19X regulates DDIT4L gene expression, specifically interacting with a region upstream of the DDIT4L gene and changing the chromatin accessibility of a DDIT4L enhancer. These events resulted in transcriptional repression of DDIT4L and, in turn, in increased collagen expression and fibrosis. Our results shed light on key effectors of TGF-β-induced ECM remodeling and fibrosis.
Collapse
Affiliation(s)
- Elena Pachera
- Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
| | - Shervin Assassi
- Division of Rheumatology, Department of Internal Medicine, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA
| | - Gloria A Salazar
- Division of Rheumatology, Department of Internal Medicine, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA
| | - Mara Stellato
- Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
| | - Florian Renoux
- Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
| | - Adam Wunderlin
- Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
| | - Przemyslaw Blyszczuk
- Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
| | - Robert Lafyatis
- Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Fina Kurreeman
- Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
| | | | - Tobias Messemaker
- Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
| | | | - Gerhard Rogler
- Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland
| | - Wouter T van Haaften
- Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, Netherlands
| | - Gerard Dijkstra
- Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, Netherlands
| | - Fiona Oakley
- Newcastle Fibrosis Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
| | - Maurizio Calcagni
- Department of Plastic Surgery and Hand Surgery, University Hospital Zurich, Zurich, Switzerland
| | - Janine Schniering
- Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
| | - Britta Maurer
- Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
| | - Jörg Hw Distler
- Department of Internal Medicine 3, University of Erlangen, Erlangen, Germany
| | - Gabriela Kania
- Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
| | - Mojca Frank-Bertoncelj
- Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
| | - Oliver Distler
- Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
| |
Collapse
|
6
|
Salazar GA, Kuwana M, Wu M, Estrada-Y-Martin RM, Ying J, Charles J, Mayes MD, Assassi S. KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease. J Rheumatol 2018; 45:1153-1158. [PMID: 29961690 DOI: 10.3899/jrheum.170518] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/29/2018] [Indexed: 12/28/2022]
Abstract
OBJECTIVE The 2 pneumoproteins, KL-6 and CCL-18, are promising biomarkers in systemic sclerosis (SSc)-related interstitial lung disease (ILD). Our goal was to determine their predictive significance for forced vital capacity % (FVC%) decline within the first year of followup in patients with early SSc-ILD. METHODS Early SSc patients with imaging-verified ILD enrolled in the Genetics versus Environment in Scleroderma Outcome Study (GENISOS) cohort were included. Annualized rate of change in FVC% based on the baseline and followup measurement within 12-18 months was used as the surrogate outcomes for ILD progression. RESULTS Eighty-two early SSc-ILD patients with mean disease duration of 2.3 years were investigated. FVC% change ranged from -23% to 38%. Baseline KL-6 levels were higher in patients than healthy controls (p < 0.0001). Higher KL-6 levels were predictive of faster FVC% decline at the 1-year followup (r = -0.23, p = 0.037). Upon categorizing KL-6 using a previously published cutoff of 1273 U/ml, its predictive significance remained in the univariable model (b = -0.07, p = 0.01), indicating that patients with positive KL-6 had on average 7% more decline in annualized percent change of FVC%. Moreover, KL-6 remained an independent predictor after adjustment for sex, disease type, anti-Scl-70, and immunosuppressive treatment status in multivariable models. Although CCL-18 was higher in patients than controls (p < 0.001), its levels did not predict FVC decline rate (p = 0.458). CONCLUSION KL-6 but not CCL-18 is predictive of early SSc-ILD progression. KL-6 is a promising pneumoprotein that can contribute to SSc-ILD clinical trial enrichment.
Collapse
Affiliation(s)
- Gloria A Salazar
- From the Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA; Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan.,G.A. Salazar, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; M. Kuwana, MD, PhD, Department of Allergy and Rheumatology, Nippon Medical School; M. Wu, MD, PhD, The University of Texas Health Science Center at Houston, McGovern Medical School; R.M. Estrada-Y-Martin, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; J. Ying, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; J. Charles, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; M.D. Mayes, MD, MPH, The University of Texas Health Science Center at Houston, McGovern Medical School; S. Assassi, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School
| | - Masataka Kuwana
- From the Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA; Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan.,G.A. Salazar, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; M. Kuwana, MD, PhD, Department of Allergy and Rheumatology, Nippon Medical School; M. Wu, MD, PhD, The University of Texas Health Science Center at Houston, McGovern Medical School; R.M. Estrada-Y-Martin, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; J. Ying, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; J. Charles, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; M.D. Mayes, MD, MPH, The University of Texas Health Science Center at Houston, McGovern Medical School; S. Assassi, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School
| | - Minghua Wu
- From the Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA; Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan.,G.A. Salazar, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; M. Kuwana, MD, PhD, Department of Allergy and Rheumatology, Nippon Medical School; M. Wu, MD, PhD, The University of Texas Health Science Center at Houston, McGovern Medical School; R.M. Estrada-Y-Martin, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; J. Ying, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; J. Charles, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; M.D. Mayes, MD, MPH, The University of Texas Health Science Center at Houston, McGovern Medical School; S. Assassi, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School
| | - Rosa M Estrada-Y-Martin
- From the Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA; Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan.,G.A. Salazar, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; M. Kuwana, MD, PhD, Department of Allergy and Rheumatology, Nippon Medical School; M. Wu, MD, PhD, The University of Texas Health Science Center at Houston, McGovern Medical School; R.M. Estrada-Y-Martin, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; J. Ying, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; J. Charles, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; M.D. Mayes, MD, MPH, The University of Texas Health Science Center at Houston, McGovern Medical School; S. Assassi, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School
| | - Jun Ying
- From the Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA; Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan.,G.A. Salazar, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; M. Kuwana, MD, PhD, Department of Allergy and Rheumatology, Nippon Medical School; M. Wu, MD, PhD, The University of Texas Health Science Center at Houston, McGovern Medical School; R.M. Estrada-Y-Martin, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; J. Ying, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; J. Charles, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; M.D. Mayes, MD, MPH, The University of Texas Health Science Center at Houston, McGovern Medical School; S. Assassi, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School
| | - Julio Charles
- From the Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA; Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan.,G.A. Salazar, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; M. Kuwana, MD, PhD, Department of Allergy and Rheumatology, Nippon Medical School; M. Wu, MD, PhD, The University of Texas Health Science Center at Houston, McGovern Medical School; R.M. Estrada-Y-Martin, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; J. Ying, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; J. Charles, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; M.D. Mayes, MD, MPH, The University of Texas Health Science Center at Houston, McGovern Medical School; S. Assassi, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School
| | - Maureen D Mayes
- From the Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA; Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan.,G.A. Salazar, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; M. Kuwana, MD, PhD, Department of Allergy and Rheumatology, Nippon Medical School; M. Wu, MD, PhD, The University of Texas Health Science Center at Houston, McGovern Medical School; R.M. Estrada-Y-Martin, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; J. Ying, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; J. Charles, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; M.D. Mayes, MD, MPH, The University of Texas Health Science Center at Houston, McGovern Medical School; S. Assassi, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School
| | - Shervin Assassi
- From the Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA; Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan. .,G.A. Salazar, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; M. Kuwana, MD, PhD, Department of Allergy and Rheumatology, Nippon Medical School; M. Wu, MD, PhD, The University of Texas Health Science Center at Houston, McGovern Medical School; R.M. Estrada-Y-Martin, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; J. Ying, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; J. Charles, MS, The University of Texas Health Science Center at Houston, McGovern Medical School; M.D. Mayes, MD, MPH, The University of Texas Health Science Center at Houston, McGovern Medical School; S. Assassi, MD, MS, The University of Texas Health Science Center at Houston, McGovern Medical School.
| |
Collapse
|
7
|
Wu M, Baron M, Pedroza C, Salazar GA, Ying J, Charles J, Agarwal SK, Hudson M, Pope J, Zhou X, Reveille JD, Fritzler MJ, Mayes MD, Assassi S. CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts. Arthritis Rheumatol 2017; 69:1871-1878. [PMID: 28575534 DOI: 10.1002/art.40171] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2016] [Accepted: 06/01/2017] [Indexed: 01/13/2023]
Abstract
OBJECTIVE There are few clinical predictors of the progression of systemic sclerosis (SSc)-related interstitial lung disease (ILD). The purpose of this study was to examine the predictive significance of key cytokines for long-term progression of ILD and survival in 2 independent cohorts of patients with early SSc. METHODS Plasma levels of 11 Th1/Th2 cytokines (interleukin-1β [IL-1β], IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, tumor necrosis factor, CCL2, interferon-inducible T cell α chemoattractant, and interferon-γ-inducible 10-kd protein) were measured in 266 patients with early SSc in the Genetics versus Environment in Scleroderma Outcome Study (GENISOS) discovery cohort. Levels of CCL2, IL-10, and IL-6 were measured in 171 patients with early SSc in the Canadian Scleroderma Research Group (CSRG) replication cohort. The primary outcome measure was a decline in the forced vital capacity percent predicted (FVC%) value over time. A joint analysis of longitudinal FVC% values and survival was performed. RESULTS After adjustment for age, sex, and ethnicity, CCL2 and IL-10 were found to be significant predictors of ILD progression in the discovery cohort. Higher CCL2 levels predicted a faster decline in FVC% values (b = -0.57, P = 0.032), while higher IL-10 levels predicted a slower decline (b = 0.26, P = 0.01). A higher CCL2 value was also predictive of poorer survival (hazard ratio 1.76, P = 0.030). In the CSRG replication cohort, higher CCL2 levels predicted a faster decline in FVC% values (b = -0.58, P = 0.038), but neither IL-10 nor IL-6 had predictive significance. A higher CCL2 level also predicted poorer survival (hazard ratio 3.89, P = 0.037). CONCLUSION Higher CCL2 levels in the circulation were predictive of ILD progression and poorer survival in patients with early SSc, findings that support the notion that CCL2 has a role as a biomarker and potential therapeutic target.
Collapse
Affiliation(s)
- Minghua Wu
- McGovern Medical School, University of Texas Health Science Center at Houston
| | | | - Claudia Pedroza
- McGovern Medical School, University of Texas Health Science Center at Houston
| | - Gloria A Salazar
- McGovern Medical School, University of Texas Health Science Center at Houston
| | - Jun Ying
- McGovern Medical School, University of Texas Health Science Center at Houston
| | - Julio Charles
- McGovern Medical School, University of Texas Health Science Center at Houston
| | | | - Marie Hudson
- Jewish General Hospital and Lady Davis Institute for Medical Research, Montreal, Quebec, Canada
| | - Janet Pope
- St. Joseph's Health Care, University of Western Ontario, London, Ontario, Canada
| | - Xiaodong Zhou
- McGovern Medical School, University of Texas Health Science Center at Houston
| | - John D Reveille
- McGovern Medical School, University of Texas Health Science Center at Houston
| | | | - Maureen D Mayes
- McGovern Medical School, University of Texas Health Science Center at Houston
| | - Shervin Assassi
- McGovern Medical School, University of Texas Health Science Center at Houston
| |
Collapse
|
8
|
Wu M, Assassi S, Salazar GA, Pedroza C, Gorlova OY, Chen WV, Charles J, Taing ML, Liao K, Wigley FM, Hummers LK, Shah AA, Hinchcliff M, Khanna D, Schiopu E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Zhou X, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Fritzler MJ, Molitor JA, Segal BM, Movahedian M, Martín J, Varga J, Mayes MD. Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. Arthritis Res Ther 2016; 18:20. [PMID: 26792595 PMCID: PMC4719560 DOI: 10.1186/s13075-016-0923-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2015] [Accepted: 01/06/2016] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND Systemic sclerosis (SSc)-related interstitial lung disease (ILD) has phenotypic similarities to lung involvement in idiopathic interstitial pneumonia (IIP). We aimed to assess whether genetic susceptibility loci recently identified in the large IIP genome-wide association studies (GWASs) were also risk loci for SSc overall or severity of ILD in SSc. METHODS A total of 2571 SSc patients and 4500 healthy controls were investigated from the US discovery GWAS and additional US replication cohorts. Thirteen IIP-related selected single nucleotide polymorphisms (SNPs) were genotyped and analyzed for their association with SSc. RESULTS We found an association of SSc with the SNP rs6793295 in the LRRC34 gene (OR = 1.14, CI 95 % 1.03 to 1.25, p value = 0.009) and rs11191865 in the OBFC1 gene (OR = 1.09, CI 95 % 1.00 to 1.19, p value = 0.043) in the discovery cohort. Additionally, rs7934606 in MUC2 (OR = 1.24, CI 95 % 1.01 to 1.52, p value = 0.037) was associated with SSc-ILD defined by imaging. However, these associations failed to replicate in the validation cohort. Furthermore, SNPs rs2076295 in DSP (β = -2.29, CI 95 % -3.85 to -0.74, p value = 0.004) rs17690703 in SPPL2C (β = 2.04, CI 95 % 0.21 to 3.88, p value = 0.029) and rs1981997 in MAPT (β = 2.26, CI 95 % 0.35 to 4.17, p value = 0.02) were associated with percent predicted forced vital capacity (FVC%) even after adjusting for the anti-topoisomerase (ATA)-positive subset. However, these associations also did not replicate in the validation cohort. CONCLUSIONS Our results add new evidence that SSc and SSc-related ILD are genetically distinct from IIP, although they share phenotypic similarities.
Collapse
Affiliation(s)
- Minghua Wu
- Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas McGovern Medical School at Houston, 6431 Fannin Street, Houston, TX, 77030, USA.
| | - Shervin Assassi
- Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas McGovern Medical School at Houston, 6431 Fannin Street, Houston, TX, 77030, USA.
| | - Gloria A Salazar
- Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas McGovern Medical School at Houston, 6431 Fannin Street, Houston, TX, 77030, USA.
| | - Claudia Pedroza
- Department of Pediatrics, The University of Texas Mcgovern Medical School at Houston, 6431 Fannin Street, Houston, TX, 77030, USA.
| | - Olga Y Gorlova
- Department of Community and Family Medicine, Geisel School of Medicine at Dartmouth, 1 Rope Ferry Road, Hanover, NH, 03755, USA.
| | - Wei V Chen
- Department of Community and Family Medicine, Geisel School of Medicine at Dartmouth, 1 Rope Ferry Road, Hanover, NH, 03755, USA.
| | - Julio Charles
- Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas McGovern Medical School at Houston, 6431 Fannin Street, Houston, TX, 77030, USA.
| | - Miranda L Taing
- Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas McGovern Medical School at Houston, 6431 Fannin Street, Houston, TX, 77030, USA.
| | - Kelley Liao
- Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas McGovern Medical School at Houston, 6431 Fannin Street, Houston, TX, 77030, USA.
| | - Fredrick M Wigley
- Division of Rheumatology, Johns Hopkins University School of Medicine, 5501 Hopkins Bayview circle, Baltimore, MD, 21224, USA.
| | - Laura K Hummers
- Division of Rheumatology, Johns Hopkins University School of Medicine, 5501 Hopkins Bayview circle, Baltimore, MD, 21224, USA.
| | - Ami A Shah
- Division of Rheumatology, Johns Hopkins University School of Medicine, 5501 Hopkins Bayview circle, Baltimore, MD, 21224, USA.
| | - Monique Hinchcliff
- Division of Rheumatology, Northwestern University Feinberg School of Medicine, 240 East Huron Street, Chicago, IL, 60611, USA.
| | - Dinesh Khanna
- Department of Internal Medicine, Division of Rheumatology, University of Michigan Health Center, 300 North Ingalls Street, Ann Arbor, MI, 48109, USA.
| | - Elena Schiopu
- Department of Internal Medicine, Division of Rheumatology, University of Michigan Health Center, 300 North Ingalls Street, Ann Arbor, MI, 48109, USA.
| | - Kristine Phillips
- Department of Internal Medicine, Division of Rheumatology, University of Michigan Health Center, 300 North Ingalls Street, Ann Arbor, MI, 48109, USA.
| | - Daniel E Furst
- Division of Rheumatology, University of California Los Angeles, 1000 Veterans Avenue, Los Angeles, CA, 90024, USA.
| | - Virginia Steen
- Division of Rheumatology, Georgetown University Medical Center, 3800 Reservoir Road, Washington, MD, 20007, USA.
| | - Murray Baron
- Division of Rheumatology, McGill University, 1650 Cedar Avenue, Montreal, QC, H3G 1A4, Canada.
| | - Marie Hudson
- Division of Rheumatology, McGill University, 1650 Cedar Avenue, Montreal, QC, H3G 1A4, Canada.
| | - Xiaodong Zhou
- Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas McGovern Medical School at Houston, 6431 Fannin Street, Houston, TX, 77030, USA.
| | - Janet Pope
- Division of Rheumatology, St. Joseph's Health Care, University of Western Ontario, 268 Grosvenor Street, London, ON, Canada.
| | - Niall Jones
- Division of Rheumatology, University of Alberta, 11405-87 Avenue, Edmonton, AB, T6G 1C9, Canada.
| | - Peter Docherty
- Division of Rheumatology, Moncton Hospital, 135 MacBeath Avenue, Moncton, NB, E1C 6Z8, Canada.
| | - Nader A Khalidi
- Division of Rheumatology, McMaster University at Hamilton, 1280 Main Street West, Hamilton, ON, L8S 4L8, Canada.
| | - David Robinson
- Division of Rheumatology, University of Manitoba, 820 Sherbrook Street, Winnipeg, MB, R3A 1R9, Canada.
| | - Robert W Simms
- Division of Rheumatology, Boston University School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA.
| | - Richard M Silver
- Division of Rheumatology, Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC, 29425, USA.
| | - Tracy M Frech
- Division of Rheumatology, University of Utah, 30 North 1900 East, Salt Lake City, UT, 84132, USA.
| | - Barri J Fessler
- Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 1825 University Boulevard, Birmingham, AB, 35294, USA.
| | - Marvin J Fritzler
- Division of Rheumatology, University of Calgary Cumming School of Medicine, 3330 Hospital Drive NW, Calgary, AB, T2N 4N1, Canada.
| | - Jerry A Molitor
- Division of Rheumatology, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN, 55455, USA.
| | - Barbara M Segal
- Division of Rheumatology, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN, 55455, USA.
| | - Malahat Movahedian
- Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas McGovern Medical School at Houston, 6431 Fannin Street, Houston, TX, 77030, USA.
| | - Javier Martín
- Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de Investigaciones Cientıficas, C/Ventanilla 11, 18001, Granada, Spain.
| | - John Varga
- Division of Rheumatology, Northwestern University Feinberg School of Medicine, 240 East Huron Street, Chicago, IL, 60611, USA.
| | - Maureen D Mayes
- Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas McGovern Medical School at Houston, 6431 Fannin Street, Houston, TX, 77030, USA.
| |
Collapse
|
9
|
Affiliation(s)
- Ana G Alzaga
- Universidad Autónoma de Tamaulipas, Tampico, Mexico
| | | | | |
Collapse
|